Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD‐1) inhibitors, has significantly advanced cancer treatment by enhancing the immune system's ability to target and eliminate malignant cells [1]. The gene discussed is PDCD1; the disease is cancer.